Outlook Therapeutics, Inc. (NASDAQ:OTLK) Forecasted to Post FY2024 Earnings of $0.08 Per Share

Outlook Therapeutics, Inc. (NASDAQ:OTLKGet Rating) – Research analysts at Brookline Capital Management raised their FY2024 earnings per share (EPS) estimates for shares of Outlook Therapeutics in a note issued to investors on Wednesday, March 1st. Brookline Capital Management analyst K. Dolliver now expects that the company will earn $0.08 per share for the year, up from their previous forecast of $0.03. The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($0.28) per share.

A number of other brokerages have also issued reports on OTLK. Cantor Fitzgerald initiated coverage on shares of Outlook Therapeutics in a research report on Monday, February 6th. They set an “overweight” rating and a $4.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Outlook Therapeutics in a research note on Wednesday, February 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Outlook Therapeutics has a consensus rating of “Buy” and an average price target of $5.75.

Outlook Therapeutics Price Performance

Shares of NASDAQ OTLK opened at $1.12 on Monday. Outlook Therapeutics has a 12 month low of $0.68 and a 12 month high of $2.12. The company has a quick ratio of 4.09, a current ratio of 4.09 and a debt-to-equity ratio of 2.02. The business’s 50 day moving average is $1.14 and its two-hundred day moving average is $1.12.

Institutional Investors Weigh In On Outlook Therapeutics

Large investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA boosted its position in Outlook Therapeutics by 174.2% in the second quarter. BNP Paribas Arbitrage SA now owns 25,837 shares of the company’s stock valued at $26,000 after buying an additional 16,414 shares in the last quarter. CI Private Wealth LLC acquired a new position in shares of Outlook Therapeutics in the 4th quarter worth approximately $31,000. Barclays PLC grew its position in Outlook Therapeutics by 533.3% during the 4th quarter. Barclays PLC now owns 31,806 shares of the company’s stock worth $34,000 after acquiring an additional 26,784 shares during the last quarter. Citadel Advisors LLC increased its holdings in Outlook Therapeutics by 210.4% during the 3rd quarter. Citadel Advisors LLC now owns 32,801 shares of the company’s stock valued at $40,000 after purchasing an additional 22,232 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Outlook Therapeutics in the 4th quarter valued at $40,000. Institutional investors own 10.61% of the company’s stock.

Insider Transactions at Outlook Therapeutics

In other Outlook Therapeutics news, insider Jeff Evanson sold 103,255 shares of the firm’s stock in a transaction dated Thursday, January 19th. The shares were sold at an average price of $1.22, for a total transaction of $125,971.10. Following the completion of the transaction, the insider now owns 1,012,975 shares in the company, valued at $1,235,829.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.00% of the stock is owned by insiders.

About Outlook Therapeutics

(Get Rating)

Outlook Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Further Reading

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.